Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma

Zheng, Jianxiong; Peng, Lei; Zhang, Shaohua; Liao, Haiyang; Hao, Jiayao; Wu, Song; Shen, Haili

doi:10.3389/fimmu.2023.1275033

Cited by 6 publications

(1 citation statement)

References 42 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The SII is defined as follows platelet count × neutrophil count/ lymphocyte count and has been found to be associated with the prognosis of several cancers, such as urothelial carcinoma, hepatocellular carcinoma, and non-metastatic RCC (12)(13)(14). The prognostic value of SII in mRCC patients treated with systemic therapy remains unclear.…”

Section: Introductionmentioning

confidence: 99%

Prognostic value of systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with systemic therapy: a meta-analysis

Xu,

Chen,

Cao

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

ObjectiveA novel systemic immune-inflammation index (SII), based on the neutrophils, lymphocytes, and platelet counts, is associated with the prognosis of several cancers, including non-metastatic renal cell carcinoma (RCC). In the present study, we evaluate the prognostic significance of SII in patients with metastatic RCC (mRCC) treated with systemic therapy.MethodRelevant studies were searched comprehensively from Web of Science, PubMed, Embase and the Cochrane Library up to January 2024. The pooled hazard ratio (HR) and 95% confidence interval (CI) were extracted from each study to evaluate the prognostic value of SII in patients with mRCC treated with tyrosine kinase inhibitor (TKI) or immune checkpoint inhibitor (ICI).ResultsA total of 12 studies including 4,238 patients were included in the final analysis. High SII was significantly correlated to poor overall survival (OS, HR = 1.88; 95% CI 1.60–2.21; P < 0.001) and progression-free survival (PFS, HR = 1.66; 95% CI 1.39–1.99; P < 0.001). Stratified by therapy, high SII was also related to the poor OS (TKI: HR = 1.63, P < 0.001; ICI: HR = 2.27, P < 0.001) and PFS (TKI: HR = 1.67, P < 0.001; ICI: HR = 1.88, P = 0.002).ConclusionIn conclusion, high SII could serve as an unfavorable factor in patients with mRCC treated with systemic therapy. Stratified by therapies, the elevated SII was also associated with worse prognosis. Whereas, more prospective and large-scale studies are warranted to validate our findings.Systematic review registrationhttps://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42024522831, identifier CRD42024522831.

show abstract

Section: Introductionmentioning

confidence: 99%

Prognostic value of systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with systemic therapy: a meta-analysis

Xu,

Chen,

Cao

et al. 2024

Front. Oncol.

View full text Add to dashboard Cite

show abstract

Prognostic value of the systemic immune-inflammation index in patients with acute respiratory distress syndrome: A retrospective study

pan,

Xu,

et al. 2024

Heliyon

View full text Add to dashboard Cite

Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer

Wang,

Tang,

Liu

et al. 2024

Sci Rep

View full text Add to dashboard Cite

Tumor inflammation is one of the hallmarks of tumors and is closely related to tumor occurrence and development, providing individualized prognostic prediction. However, few studies have evaluated the relationship between inflammation and the prognosis of bladder urothelial carcinoma (BLCA) patients. Therefore, we constructed a novel inflammation-related prognostic model that included six inflammation-related genes (IRGs) that can precisely predict the survival outcomes of BLCA patients. RNA-seq expression and corresponding clinical data from BLCA patients were downloaded from The Cancer Genome Atlas database. Enrichment analysis was subsequently performed to determine the enrichment of GO terms and KEGG pathways. K‒M analysis was used to compare overall survival (OS). Cox regression and LASSO regression were used to identify prognostic factors and construct the model. Finally, this prognostic model was used to evaluate cell infiltration in the BLCA tumor microenvironment and analyze the effect of immunotherapy in high- and low-risk patients. We established an IRG signature-based prognostic model with 6 IRGs (TNFRSF12A, NR1H3, ITIH4, IL1R1, ELN and CYP26B1), among which TNFRSF12A, IL1R1, ELN and CYP26B1 were unfavorable prognostic factors and NR1H3 and ITIH4 were protective indicators. High-risk score patients in the prognostic model had significantly poorer OS. Additionally, high-risk score patients were associated with an inhibitory immune tumor microenvironment and poor immunotherapy response. We also found a correlation between IRS-related genes and bladder cancer chemotherapy drugs in the drug sensitivity data. The IRG signature-based prognostic model we constructed can predict the prognosis of BLCA patients, providing additional information for individualized prognostic judgment and treatment selection.

show abstract

Preoperative systemic immune-inflammation index as a prognostic indicator for patients with urothelial carcinoma

Cited by 6 publications

References 42 publications

Prognostic value of systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with systemic therapy: a meta-analysis

Prognostic value of systemic immune-inflammation index in patients with metastatic renal cell carcinoma treated with systemic therapy: a meta-analysis

Prognostic value of the systemic immune-inflammation index in patients with acute respiratory distress syndrome: A retrospective study

Identification of an inflammation-related risk signature for prognosis and immunotherapeutic response prediction in bladder cancer

Contact Info

Product

Resources

About